Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Pfizer announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopaedic surgery in the first half of 2010.
The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of for prevention of VTE in patients undergoing orthopaedic surgery.

Dec 7 · 4:26:00 PM · Source: Pharmabiz.com · Related: Pfizer
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto